Regeneron Announces Upcoming Investor Conference Presentations

TARRYTOWN, N.Y., May 5, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. REGN will webcast management presentations as follows:

  • J.P. Morgan 2017 Spring Conference Call Series at 10:00 a.m. Eastern Time on Thursday, May 11, 2017
  • Bank of America Merrill Lynch 2017 Healthcare Conference at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) on Tuesday, May 16, 2017
  • Barclays 2017 Biopharmaceuticals CEO/CFO Conference Call Series at 11:00 a.m. Eastern Time on Friday, May 19, 2017

The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  Archived versions of the presentations will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron REGN is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol, atopic dermatitis and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:




Investor Relations                    

Corporate Communications

Manisha Narasimhan, Ph.D.    

Hala Mirza

914.847.5126                         

914.847.3422                       

manisha.narasimhan@regeneron.com  

hala.mirza@regeneron.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentations-300452231.html

SOURCE Regeneron Pharmaceuticals, Inc.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!